![]() I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. All patients provided written informed consent. Data were acquired under institutional agreement and the study was approved by each institutional review board. These samples came from the following institutional sources: Accelerated Cure Project (Waltham, MA, USA), Brigham and Women's Hospital (Boston, MA, USA), University of California San Francisco (San Francisco, CA, USA), University Hospital Basel (Basel, Switzerland), American University Beirut (Beirut, Lebanon), University of Massachusetts (Boston, MA, USA), University of Pittsburgh (Pittsburgh, PA, USA) and Rocky Mountain Multiple Sclerosis Clinic (Salt Lake City, UT, USA). Serum samples from patients with multiple sclerosis (MS) were analyzed during the assay development and validation process to establish the MS reference ranges for each analyte. Serum samples from publicly available sources were analyzed for analytical validation experiments. The study used both publicly available data and data acquired under institutional agreement. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Department of Defense (W81XWH2110633 to T Chitnis). The study was funded by Octave Bioscience, Inc. Chitnis has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research support from the National Institutes of Health, National MS Society, US Department of Defense, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis Pharmaceuticals, Octave Bioscience, Inc., Roche Genentech, and Tiziana Life Sciences. Foley has received research support from Biogen, Novartis, Adamas, Octave Bioscience, Inc., Genentech, and Mallinckrodt, received speakers' honoraria and acted as a consultant for EMD Serono, Genzyme, Novartis, Biogen, and Genentech, and has equity interest in Octave Biosciences Inc., and is the founder of InterPro Biosciences. Becich was an employee of Octave Biosciences, Inc. Zhang are employees of Octave Bioscience, Inc. Conclusions and clinical relevance Analytical validation of this serum-based proteomic multiplex assay is the first step in establishing its potential utility as a quantitative, minimally invasive, and scalable biomarker panel to enhance the standard of care for patients with MS.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |